Myconostica Announces CE Marking of MycAssayTM Product Family on Additional Platforms

Myconostica Announces CE Marking of MycAssayTM Product Family on Additional Platforms
Manchester, United Kingdom, August 9, 2010 / b3c newswire / - Myconostica Ltd, the UK-based medical diagnostic company developing and commercialising rapid and highly specific tests for life-threatening fungal infections, today announces the CE marking of its lead products MycAssayTM Aspergillus and MycAssayTM Pneumocystis on the Roche Lightcycler® 2.0 and Stratagene Mx3000 series platforms.

The CE marking on these two platforms in addition to the existing CE marking on the Cepheid Smartcycler® and Applied Biosystems ABI 7500 means these products are now available on the four real-time PCR machines most common in clinical microbiology and mycology laboratories.
MycAssayTM Pneumocystis is a molecular diagnostic test for the detection of Pneumocystis jirovecii DNA in lower respiratory tract samples. The kit is designed to be used by qualified laboratory professionals; the results provided by MycAssayTM Pneumocystis aid physicians to make a diagnosis in patients suspected of having an infection caused by Pneumocystis jirovecii.

MycAssayTM Aspergillus is a molecular diagnostic test for the detection of Aspergillus spp DNA in lower respiratory tract samples. The kit is designed to be used by qualified laboratory professionals; the results provided by MycAssayTM Aspergillus aid physicians to make a diagnosis in patients suspected of having an infection caused by Aspergillus.

When used in conjunction with Myconostica's fungal DNA extraction system, MycXtra®, a result can be obtained within 3 hours of sample receipt. The MycAssayTM products provide rapid and accurate results to physicians, enabling appropriate drug treatments to be administered thereby improving patient outcomes.

Dr. John Thornback, Myconostica's Chief Business Officer, said  "We are committed to developing diagnostics for  life threatening diseases and we are dedicated to making our products available to the widest possible customer base. We recognise that our customers in the clinical laboratories have multiple opportunities for real-time PCR platforms and so we have an intensive ongoing programme to adapt our assays to fit in with our customers. These latest CE marks are part of that successful programme".

About Myconostica Ltd. - www.myconostica.co.uk
Myconostica Ltd, a UK-based medical diagnostic company, specialises in rapid and highly specific tests for life-threatening fungal infections. Traditional methods of the detection of fungal infections are well documented as being relatively insensitive and slow.  Tests provided by Myconostica aim to allow healthcare professionals to rapidly identify patients infected thus enabling clinicians to prescribe appropriate drug therapy.
Myconostica is developing and commercialising a portfolio of real-time molecular diagnostic tests for life-threatening fungal infections. Over 10 million people are at risk of these infections each year in Europe and North America alone.
 
For further information please contact:

Myconostica Ltd
Heidi Wahlefeld-Moghimi
[email protected]
+44 (0)161 998 7239

Suggested Articles

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.

The series B positions ex-AveXis executives to build a biotech with a broad gene therapy pipeline and infrastructure to match.

A variant of the ACE2 receptor could work as a COVID-19 therapeutic by drawing the virus away from healthy cells, scientists reported.